Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
GlaxoSmithKline Plc (GSK) will reveal detailed results today on an experimental treatment for diabetes that?s part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (HGSI) (HGSI), its partner on the drug.
Glaxo will present data from two of eight late-stage studies, dubbed Harmony 6 and Harmony 7, of the once-weekly drug albiglutide ahead of the American Diabetes Association?s annual meeting next month. Abstracts of those studies will be posted on the ADA website today.
Albiglutide, along with the lupus treatment Benlysta and darapladib for heart disease, form a trio of drugs Glaxo has developed with Human Genome. If approved, the product would compete with existing medicines from Amylin Pharmaceuticals Inc. (AMLN) (AMLN) and Novo Nordisk A/S (NOVOB), as well as other late-stage experimental drugs being developed by Sanofi and Eli Lilly & Co. (LLY) (LLY), said Ying Huang, a Barclays Capital Inc. analyst in New York.
http://www.businessweek.com/news/2012-05-24/glaxo-diabetes-drug-data-revealed-amid-hostile-takeover
Glaxo will present data from two of eight late-stage studies, dubbed Harmony 6 and Harmony 7, of the once-weekly drug albiglutide ahead of the American Diabetes Association?s annual meeting next month. Abstracts of those studies will be posted on the ADA website today.
Albiglutide, along with the lupus treatment Benlysta and darapladib for heart disease, form a trio of drugs Glaxo has developed with Human Genome. If approved, the product would compete with existing medicines from Amylin Pharmaceuticals Inc. (AMLN) (AMLN) and Novo Nordisk A/S (NOVOB), as well as other late-stage experimental drugs being developed by Sanofi and Eli Lilly & Co. (LLY) (LLY), said Ying Huang, a Barclays Capital Inc. analyst in New York.
http://www.businessweek.com/news/2012-05-24/glaxo-diabetes-drug-data-revealed-amid-hostile-takeover